Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBIT: 2019-2025

Historic EBIT for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$15.4 million.

  • Keros Therapeutics' EBIT rose 73.77% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 121.36%. This contributed to the annual value of -$210.8 million for FY2024, which is 24.06% down from last year.
  • Keros Therapeutics' EBIT amounted to -$15.4 million in Q3 2025, which was up 61.36% from -$39.8 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EBIT registered a high of $152.0 million during Q1 2025, and its lowest value of -$58.7 million during Q3 2024.
  • Over the past 3 years, Keros Therapeutics' median EBIT value was -$43.3 million (recorded in 2023), while the average stood at -$25.8 million.
  • Per our database at Business Quant, Keros Therapeutics' EBIT slumped by 556.80% in 2022 and then surged by 413.59% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' EBIT stood at -$4.9 million in 2021, then tumbled by 556.80% to -$32.0 million in 2022, then plummeted by 45.35% to -$46.5 million in 2023, then fell by 14.64% to -$53.3 million in 2024, then soared by 73.77% to -$15.4 million in 2025.
  • Its EBIT was -$15.4 million in Q3 2025, compared to -$39.8 million in Q2 2025 and $152.0 million in Q1 2025.